CD276 and cancer: Early preclinical and clinical results of B7-H3 inhibition have demonstrated encouraging anti-cancer activity but better understanding of the dynamic interplay of B7-H3 with the other TME constituents would be essential for its optimal targeting; while combined inhibition of B7-H3 with other ICs could synergistically overcome resistance to currently administered CPIs.